The role of lysosomal cathepsins in neurodegeneration: Mechanistic insights, diagnostic potential and therapeutic approaches.

Alzheimer's disease Cathepsins Huntington's disease Lysosome Neurodegeneration Neuronal ceroid lipofuscinosis Parkinson's disease Synucleinopathies α-Synuclein

Journal

Biochimica et biophysica acta. Molecular cell research
ISSN: 1879-2596
Titre abrégé: Biochim Biophys Acta Mol Cell Res
Pays: Netherlands
ID NLM: 101731731

Informations de publication

Date de publication:
07 2022
Historique:
received: 30 06 2021
revised: 08 02 2022
accepted: 10 02 2022
pubmed: 27 2 2022
medline: 12 4 2022
entrez: 26 2 2022
Statut: ppublish

Résumé

Lysosomes are ubiquitous organelles with a fundamental role in maintaining cellular homeostasis by mediating degradation and recycling processes. Cathepsins are the most abundant lysosomal hydrolyses and are responsible for the bulk degradation of various substrates. A correct autophagic function is essential for neuronal survival, as most neurons are post-mitotic and thus susceptible to accumulate cellular components. Increasing evidence suggests a crucial role of the lysosome in neurodegeneration as a key regulator of aggregation-prone and disease-associated proteins, such as α-synuclein, β-amyloid and huntingtin. Particularly, alterations in lysosomal cathepsins CTSD, CTSB and CTSL can contribute to the pathogenesis of neurodegenerative diseases as seen for neuronal ceroid lipofuscinosis, synucleinopathies (Parkinson's disease, Dementia with Lewy Body and Multiple System Atrophy) as well as Alzheimer's and Huntington's disease. In this review, we provide an overview of recent evidence implicating CTSD, CTSB and CTSL in neurodegeneration, with a special focus on the role of these enzymes in α-synuclein metabolism. In addition, we summarize the potential role of lysosomal cathepsins as clinical biomarkers in neurodegenerative diseases and discuss potential therapeutic approaches by targeting lysosomal function.

Identifiants

pubmed: 35217144
pii: S0167-4889(22)00034-9
doi: 10.1016/j.bbamcr.2022.119243
pii:
doi:

Substances chimiques

alpha-Synuclein 0
Cathepsins EC 3.4.-

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

119243

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Alice Drobny (A)

Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.

Susy Prieto Huarcaya (S)

Institute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany.

Jan Dobert (J)

Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.

Annika Kluge (A)

Department of Neurology, Christian-Albrechts-University Kiel, Kiel, Germany.

Josina Bunk (J)

Institute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany.

Theresia Schlothauer (T)

Institute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany.

Friederike Zunke (F)

Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. Electronic address: friederike.zunke@fau.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH